As per the terms of the collaboration deal, the companies will supply their respective products and equally share the trial costs. Genentech will manage the trial, which expects
The growth, which represents a compound annual growth rate of 13.6%, will take place in the US, France, Germany, Italy, Spain, the UK, and Japan, the seven major
The agreement is in connection with the divestiture process mandated by the US Federal Trade Commission (FTC) in relation toTeva’s $40.5bn acquisition of Allergan’s generic drugs portfolio. Impax
The company dosed the first subject in a phase 2b double-blind, randomized, placebo-controlled trial of its norovirus vaccine candidate, TAK-214, which will target the leading cause of acute
The initiation of a ND submission to the US Food and Drug Administration (FDA) is ahead of the company’s earlier unveiled schedule. The company’s NDA is a rolling
Sectoral Asset Management led the round, which included participants such as Novo A/S, Aisling Capital and Brace Pharma Capital. Existing investors Advent Life Sciences, Novartis Venture Fund, Sunstone
Eflornithine is a novel cytostatic agent, which is being developed to treat patients with recurrent anaplastic astrocytoma, a rare form of central nervous system cancer. The drug irreversibly
The approval, including in the UK, Germany and Spain, is for the biosimilarity study part of the phase 3 program, which is designed to allow interchangeability with Humira
The study demonstrated that Keytruda was superior to chemotherapy as measured by progression-free survival (PFS) and overall survival (OS). Based on the positive results, the independent data monitoring
The five-story, 175,000-square-foot addition to Pfizer’s Andover campus is expected to be completed in January 2019. The facility will house about 75 employees who will produce vaccines and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.